Diabetes medications can be lifesaving drugs that come with life-threatening risks. As new diabetes drugs are approved by the FDA despite alarming side effects, a vicious pharmaceutical cycle seems to be repeating itself: Patients take drugs that raise their risk of developing type 2 diabetes, only... Read More
A master complaint was drafted on behalf of all plaintiffs who have filed Byetta and Januvia lawsuits under MDL 2452 against all named defendants. The complaint combines general questions of fact and law common to the incretin mimetic lawsuits pending under multidistrict litigation. “This Master... Read More
Januvia lawsuits are still a long way off, but the judge is moving forward with science hearings to learn more about incretin mimetic diabetes drugs.
The findings of a recent study on incretin mimetics should strengthen allegations raised in Byetta and Januvia lawsuits that claim the diabetes drugs caused acute pancreatitis and cancer of the pancreas. Italian researchers published their results in the medical journal Expert Opinion on Drug Safety... Read More
Plaintiffs approaching their deaths due to pancreatic cancer now have a process to schedule In Extremis depositions to preserve their testimony for use during Januvia and Byetta lawsuits in federal court against their manufacturers and those of other incretin mimetic diabetes drugs. Plaintiffs’ claims in Januvia and... Read More
A group of attorneys representing plaintiffs with Janumet, Byetta, Victoza, and Januvia lawsuits filed under the incretin mimetics multidistrict litigation, currently pending in the Southern District of California, have been appointed to various leadership roles during coordinated pretrial proceedings. Federal Judge Anthony Battaglia held an... Read More
Another Januvia wrongful death lawsuit was filed in federal court in California earlier this month, alleging the makers of the popular diabetes medication failed to warn doctors and patients the drug could cause pancreatic cancer. The plaintiff, Teresa Sharit of Gardendale, Alabama, brought the lawsuit... Read More
In August 2013, the U.S. Judicial Panel on Multidistrict Litigation (JPML) decided to consolidate all products liability claims brought in federal courts nationwide involving incretin mimetics – a controversial class of diabetes drugs that have been linked to pancreatitis and cancer of the pancreas. The... Read More